FDA Seeks Public Input To Develop Guidance For Nanotechnology In Pharmaceuticals
This article was originally published in The Pink Sheet Daily
Sept. 8 public meeting requests input on safety, efficacy points to consider for using nanotech in drugs, biologics.
You may also be interested in...
2007 was an awful year for drug delivery companies, and 2008 is shaping up to be no better. The share prices of many drug delivery companies are trading at or below their 10-year averages as investors realize that convenient delivery of large molecules that heretofore required painful injections isn't necessarily a compelling commercial opportunity. Still, intrepid venture capitalists are investing in some companies that are capitalizing on one key difference: these fledgling start-ups use nanotechnology to create therapies that are significantly different--especially in terms of safety and efficacy--from the first-generation drugs they hope to supplant.
BIND Biosciences generates nanoparticles with unique targeting agents that allow them to home in on cancerous cells with deadly precision. Because it's impossible to mathematically design the optimal particle, BIND scientists have created large combinatorial libraries of nanoparticles with different biophysical and chemical properties.
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.